ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener 🦋 Butterfly 8 Analysts 🏛️ Policy 🎬 Video ★ Watchlist 🎲 Prediction Markets 📊 RQD Track Record 📅 Next Catalysts 🛡️ Overlap & Crash X-Ray 📰 Live Wire 🐋 13F Whales 🏛️ Congress & CEO Buys 🏆 $100K Arena ⌘ Pro Terminal 📐 Methodology & Corrections
Stock Ratings / Health Care / KRYS / earnings
PCVX (49) IBRX (37) KYMR (50) QGEN (71) ⌘ Pro Terminal →

Krystal Biotech Inc. (KRYS) Next Earnings Date & Expected ±6.1% Move

$332.29 +2.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $334.51

Krystal Biotech Inc. (KRYS) earns a Roarable Rating of B (Buy) with 72/100 RQD Confidence. High-quality cash engine (steady margins, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate) →
ROARABLE B • BUY Cap $9.61B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KRYS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is KRYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-02, Krystal Biotech Inc. (NASDAQ: KRYS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $332.29 (+2.38% 1D, market cap $9.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, KRYS ranks #68 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does KRYS compare to PCVX and IBRX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KRYS carries a Roarable B (72/100 RQD), trailing P/E of 46.9x, gross margin of —, and ROIC of 16.5%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B) and IBRX (ImmunityBio Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -27.3%, cap $9.26B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KRYS?
▼

Per KRYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711279), Krystal Biotech Inc. generated $389.1M in revenue (+33.9% YoY), $204.8M in net income, and $188.9M in free cash flow against $1.33B in total assets and $51.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $334.52 (+0.67%)🧬 Disciplined Float (-0.04% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 48.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 72/100 (B) historically ranked in the Top 13% of excess returns over the next 90 days (+7.0% avg 90D alpha vs SPY • 68.7% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B
025507510072
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk A-
Cash (17)Whales (10)SEC (18)Macro (15)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+6.3% Base Target
$417 Bull$353 Base$272 Bear
📬 FREE KRYS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KRYS)Realized 20D OHLCV Swing Band: ±6.1%
Deterministic 5-Pillar Attribution (72/100 Composite)
🔍 WHY KRYS SCORES 72/100 (B) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+18/20 pts (25% of score)

Altman Z-Score 26.00 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Cash Engine Quality+17/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 48.5% FCF Margin ($188.9M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning10/20 pts (-10 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-10 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
64
Grade C+$321.16+1.3% Next Q
Q2 (-2Q)
67
Grade B-$325.42-1.5% Next Q
Q3 (-1Q)
69
Grade B-$320.58+3.7% Next Q
Current
72
Grade B$332.29+7% Hist 90D α
Trajectory: C+ (64) → B (72)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the KRYS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 72/100 (B) score, KRYS faces multiple-compression risk if 46.9x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.04% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($336.68) or 200D SMA ($308.94) invalidates the momentum regime and cuts Target Base ($353.22) toward Bear Floor ($272.48).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KRYS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “KRYS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 72%NO 28%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~57 DAYS)

Historical OHLCV Volatility ±6.1% Swing Band

±$20.27 Expected Swing
$312.02 (-6.1%)Spot $332.29$352.56 (+6.1%)
MODEL EARNINGS SETUP GAUGE

KRYS Quantitative Pre-Earnings Setup: 72/100

Trailing EPS: $6.92 • YoY Revenue Growth: 33.9%

Model Bullish Setup (72/100)Model Risk Weight (28/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$389.1M$204.8M$188.9M52%
FY 20242024-12-31$290.5M$89.2M$119.2M52%
FY 20232023-12-31$50.7M$10.9M-$91.1M52%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating KRYS & AI Leaders Without Chasing Tops

  • ✓Institutional whale strikes & implied earnings move audit on KRYS
  • ✓How disciplined traders manage risk using pre-published trigger & invalidation levels
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
KRYS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +15.80%📐 WEDGE COMPRESSION COIL
2026-11-02O $321.4H $332.3L $321.4C $332.3VOL 190.9K
RES: $364.9SUP: $310.9SMA50: $336.7SMA200: $308.9
$394.0$346.4$298.8$251.2$203.6RES $364.9SUP $310.9$332.32026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KRYS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KRYS Butterfly Map → + Track KRYS →
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
34.6%/yr Implied 5Y Growth

vs. +33.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KRYS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KRYS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KRYS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KRYS)

Health Care Rank #68 of 1016 ⚔️ PCVX vs KRYS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KRYS vs. PCVX, IBRX, KYMR, QGEN)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Krystal Biotech Inc. (KRYS) ranks #68 by composite RQD confidence (72/100, grade B) and #117 by equity capitalization ($9.61B). Within this direct 5-issuer industry benchmark cohort, QGEN leads on earnings valuation at 24.4x trailing P/E, while KRYS leads on capital efficiency and profitability with 16.5% ROIC and — gross margin. KRYS currently leads its immediate peer cohort in composite quantitative strength at 72/100 (B).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KRYS ACTIVE
Krystal Biotech Inc.
B 72/100 46.9x — 16.5% +2.38% $9.61B Benchmark Subject
PCVX
Vaxcyte Inc.
D 49/100 — — -27.6% -0.93% $9.85B /pcvx-vs-krys →
IBRX
ImmunityBio Inc.
D- 37/100 — 96.0% -27.3% -5.15% $9.26B /ibrx-vs-krys →
KYMR
Kymera Therapeutics Inc.
D 50/100 32.7x — -21.4% +3.29% $10.19B /kymr-vs-krys →
QGEN
Qiagen N.V.
B- 71/100 24.4x 62.2% 8.0% -0.24% $10.37B /qgen-vs-krys →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001711279

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Krystal Biotech Inc. (KRYS) reported GAAP revenue of $389.1M (+33.9% vs. FY2024 revenue of $290.5M , and +667.5% cumulative change since FY2023) , GAAP net income of $204.8M, operating cash flow of $200.9M, and free cash flow of $188.9M (+58.5% YoY). On the balance sheet, KRYS closed FY2025 with $1.33B in total assets against $51.4M in total debt (Altman Z-Score: 26.00, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $389.1M $204.8M $200.9M $188.9M $1.33B $51.4M
FY2024 (FY) 2024-12-31 $290.5M $89.2M $123.4M $119.2M $1.06B $49.3M
FY2023 (FY) 2023-12-31 $50.7M $10.9M -$88.8M -$91.1M $5.28B $1.24B

3. KRYS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KRYS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Krystal Biotech Inc. (NASDAQ: KRYS) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 72/100 at a spot price of $332.29 (+2.38% 1D, market cap $9.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 18/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, KRYS ranks #68 in composite RQD confidence.

How does KRYS compare to PCVX and IBRX in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), KRYS carries a Roarable B (72/100 RQD), trailing P/E of 46.9x, gross margin of —, and ROIC of 16.5%. By comparison, PCVX (Vaxcyte Inc.) holds a D grade (49/100 RQD, P/E N/A, ROIC -27.6%, cap $9.85B) and IBRX (ImmunityBio Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -27.3%, cap $9.26B). Among the 5-stock peer group, QGEN leads on earnings multiple (24.4x) while KRYS leads on capital efficiency (16.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KRYS?

Per KRYS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001711279), Krystal Biotech Inc. generated $389.1M in revenue (+33.9% YoY), $204.8M in net income, and $188.9M in free cash flow against $1.33B in total assets and $51.4M in total debt. Key quantitative strengths: Strong cash generator (steady margins)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KRYS trading relative to its 50-day, 200-day, and 52-week technical levels?

KRYS last traded at $332.29 (+2.38% on volume of 330,472 shares), positioning the stock -1.30% below its 50-day simple moving average ($336.68) and +7.56% above its 200-day simple moving average ($308.94). Across its 52-week range of $184.02 to $382.54, KRYS sits at the 74.7% percentile with a 14-day RSI of 48.2 (NEUTRAL RANGE) and an implied next-earnings move of ±6.1% ($312.02 to $352.56).

KRYS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is KRYS's next earnings date?

Based on SEC filing cadence, Krystal Biotech Inc. (KRYS)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is KRYS stock expected to move on earnings?

Volatility modeling currently projects a ±6.1% event move for KRYS, spanning a range between $312.02 and $352.56.

Direct Sub-Reports: KRYS RQD Cockpit KRYS 12M Forecast KRYS Earnings & Move KRYS Dividends & DRIP KRYS Insiders & 13F KRYS Whale Options KRYS Profit Sankey KRYS News & Why
ROARABLE RATING BRIEF • RQD 72/100 (B) ✓ STAGE-C NUMBER FIREWALL VERIFIED

KRYS — Krystal Biotech Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:16:54Z

Roarable Rating Brief: What This Means to a Prospective Investor

The per the Roarable RQD rating, KRYS scores 72 out of 100, grading B, with the verdict "Roarable Buy — Good Risk/Reward." The five pillars are:

  • Fundamental Cash Engine: 17 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of 16.5% and an FCF yield of 1.97%. For an investor, this is the strongest evidence that the business converts capital into returns, though the low FCF yield means the market is paying a high price for each dollar of free cash flow.
  • Whale 13F Flow: 10 / 20. Per the Roarable RQD rating, this pillar captures institutional accumulation and options positioning. The moderate score suggests institutional support is present but not dominant; no 13F detail is provided beyond the score.
  • Insider Conviction: 12 / 20. Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow. A mid-range score indicates insider signals are neither a strong endorsement nor a warning.
  • Macro Regime Fit: 15 / 20. Per the Roarable RQD rating, this pillar reflects beta of 0.91 and sector sensitivity. A beta below 1 implies the stock has historically moved less than the market, a defensive trait that benefits investors in volatile regimes but may lag in strong rallies.
  • Forensic Balance Sheet: 18 / 20. Per the Roarable RQD rating, this pillar reflects Altman Z of 26, Piotroski F of 8/9, and Debt/Equity of 0.04. This is the strongest pillar and indicates low financial distress risk.

Valuation tradeoff: per the market data, the stock trades at a trailing P/E of 46.9 and an EV/EBITDA of 53.4, which the Roarable RQD rating does not separately penalize within its five pillars. An investor should weigh the strong forensic and cash-generation scores against the premium multiples and the 1.97% FCF yield when evaluating the stock today. This is an analytical framing, not personalized advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
324.55$9.61B46.939.453.46.920%0.91$184.02 - $382.5416.5%

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$389.1M$161.3M$204.8MN/A$188.9M$496.3M$51.4M
FY 2024$290.5M$65.7M$89.2MN/A$119.2M$344.9M$49.3M
FY 2023$50.7M$-109.6M$10.9MN/A$-91.1MN/A$1236.3M

Per the SEC financials, revenue rose from $50.7M in FY 2023 to $389.1M in FY 2025, and operating income moved from $-109.6M to $161.3M over the same span. Per the market data, the operating margin is 41.5% and the net margin is 52.6%, with ROIC at 16.5%. Per the Roarable RQD rating, the Altman Z-Score is 26 and the Piotroski F-Score is 8/9. Per the SEC financials, debt fell from $1236.3M in FY 2023 to $51.4M in FY 2025, and the RQD rating reports Debt/Equity of 0.04. Gross margin is reported as 0% in the market data and should be treated as unreliable without further context.

Open Questions

  • What are the company's specific products, approved indications, and revenue concentration, given the profile provides only sector and industry labels?
  • What drove the move from $50.7M revenue in FY 2023 to $389.1M in FY 2025, and is that growth sustainable?
  • Why is gross margin reported as 0%, and what is the true cost structure?
  • Which institutions hold KRYS, and how have their positions changed over time?
  • How do analysts value the stock relative to a 46.9 trailing P/E and 53.4 EV/EBITDA?

KRYS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Krystal Biotech Inc. (KRYS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to KRYS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KRYS Bull vs. Bear Conversation Board — What's Your Call at $332.29?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KRYS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on KRYS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐂 BULLISH 🎯 Target: $382.97 (+18.0%)
📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is KRYS (B • RQD 72/100) a Buy at $324.55?

Welcome to the KRYS (Krystal Biotech Inc.) Roar Pit. Current RQD Composite is 72/100 (Roarable Buy — Good Risk/Reward) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to capital efficiency (16.5% ROIC), while bears focus on valuation multiple compression (46.9x trailing P/E). Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $272.62 (-16.0%)
Spot @ $324.55

Pump the brakes on KRYS — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on KRYS, but look at what you are paying: 46.9x trailing P/E with tightening sector spreads. Unless Krystal Biotech Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

MA MacroHawk_NYC Verified K Arena Trader 🐂 BULLISH 🎯 Target: $386.21 (+19.0%)
Spot @ $324.55

KRYS cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on KRYS, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $324.55 (52-wk range $184.02 - $382.54), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%